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Nucleotides are released in the extracellular fluid by cell lysis, exocytosis, secretion of granules, efflux and upon cellular stress such as changes in osmolarity and mechanical perturbations. Once released, they mediate their effect by stimulation of nucleotide receptors.
Based on pharmacological properties, the first suggestion for the existence of ionotropic P2X receptors and metabotropic P2Y receptors was made by Burnstock and Kennedy [6] . After cloning, multiple subtypes of P2X and P2Y receptors were characterised unambiguously (Abbracchio and Burnstock [7] Burnstock and Williams [3] ; Fredholm et al. [8] ).
Up to now, the P2Y receptor family comprises at least eight subtypes, P2Y 1 , P2Y 2 , P2Y 4 , P2Y 6 , P2Y 11 , P2Y 12 , P2Y 13 and the recently identified P2Y 14 receptor (Ralevic and Burnstock, [5] Abbracchio et al. [9] ; Communi et al. [10] ; Hollopeter et al. [11] ; Zhang et al. [12] ). According to the agonist profile, P2Y receptors can be subdivided into receptors responding to adenine mono-and dinucleotides (P2Y 1 , P2Y 11 , P2Y 12 , P2Y 13 ), and to uridine nucleotides (P2Y 4 , P2Y 6 ), and receptors for adenine and uridine nucleotides (P2Y 2 ). The pharmacological profile of the recently cloned P2Y 14 receptor is distinct from the other P2Y receptors since UDP-glucose, UDP-galactose, UDP-glucuronic acid and UDP-N-acetylglucosamine are specific ligands of this receptor (Chambers et al. [13] ). Natural P2Y receptor ligands do not exclusively bind to one receptor subtype. ADP is an agonist of P2Y 1 , P2Y 12 and P2Y 13 receptors, whereas ATP is a full agonist of P2Y 2 and P2Y 11 , but a partial agonist or antagonist of P2Y 1 , P2Y 12 and P2Y 13 receptors. Although the pharmacological properties of P2Y receptors (Table 1) are well conserved between species, some remarkable differences have been observed. While UTP acts as an agonist of both human and rat P2Y 4 receptors, ATP is a potent agonist of the rat P2Y 4 , but an antagonist of the human orthologue. Mutational analysis revealed that the second extracellular loop of the P2Y 4 receptor is responsible for the opposing effect of ATP in both species (Herold et al. [14] ). A similar phenomenon is observed when human and canine P2Y 11 receptors were stably expressed in CHO-K1 and 1321N1 astrocytoma cells. Whereas the ). Reactive blue 2 is not included in the list since it displays lack of specificity towards the different P2Y subtypes. References: Abbracchio et al. [9] ; Communi et al. [10, 191] ; Chambers et al. [13] [192] ; Muller [193] ; Skelton et al. [194] ; Yerxa et al. [195] ; Jacobson et al. [196] ; von Ku¨gelgen [197] . Abbreviations:
human P2Y 11 is potently activated by adenosine triphosphate nucleotides, the canine orthologue displayed more selectivity towards the corresponding diphosphates. In this case, the nucleotide selectivity is due to differences in the amino acid sequence at the juxtaposition of TM6 and the third extracellular loop also reported to play an important role in agonist selectivity and signalling of other G protein-coupled receptors (GPCR [62] ). From co-expression studies of P2Y receptors with GIRK1 or GIRK2 in rat sympathetic neurons, it was concluded that P2Y receptors activate GIRK channels by the "+ subunits of G i/o and inhibit these channels by the ! subunits of G q (Filippov et al. [63] ).
P2Y-induced calcium release is followed by opening of voltage-independent Ca 2+ channels. Although this response is observed in a variety of cell types, the physiological implications are miscellaneous. In this context, it has been reported that extracellular ATP induces a Ca 2+ wave that propagates through neighbouring astrocytes by GAP junctions (Suadicani et al. [64] ). In situations of increased neuronal activity or cell damage, ATP stimulates a Ca 2+ -dependent protonefflux from astrocytes. Acidification of the extracellular environment serves as a negative feedback mechanism for neurotransmitter release, but also increases blood flow by vasodilatation in cerebral arterioles (Dienel and Hertz [65] ; Dixon et al. [66] ). Although Ca 2+ signalling is observed in a variety of cell types, the time dependence of the response is cell type specific. This is especially the case for the P2Y 1 A well-known response to PLC-generated DAG and IP 3 /Ca 2+ is the activation of classical PKCs that are involved in rapid internalisation and desensitisation of GPCRs through phosphorylation of residues localised in their cytoplasmic tail. In this regard, PKC"I is reported to attenuate phosphatidylinositol (PI)-hydrolysis induced by P2Y 1 and P2Y 2 receptors in endothelial cells (Chen and Lin [69] ). In astrocytes, high frequency stimulation of the P2Y 1 receptor by repeated addition of ATP causes rapid suppression of the P2Y 1 receptorinduced Ca 2+ response. This phenomenon, observed as Ca 2+ oscillations, is mediated by protein kinase Cdependent phosphorylation of Thr339 in the carboxyterminus of the P2Y 1 receptor (Fam et al. [70] ). Besides modulation of receptor responsiveness, PKC signalling also affects long term effects. In the human osteoblastic HOBIT cell line, ATP increases expression of the early growth response protein-1 by a mechanism that requires a Ca 2+ -independent PKC isoform (Pines et al. [71] ). In vascular smooth muscle cells, UDP stimulates cell cycle progression by a PLC-and PKC%-dependent cascade (Hou et al. [72] ). The same isoform is involved in ATPmediated mitogenic signalling in astrocytes, but in these cells PKC% activation does not involve PLC but requires PLD-dependent choline formation (Neary et al. [73] ).
In addition to PLC-coupled receptors, a growing number of P2Y receptors have been shown to affect the activity of AC. Besides the existence of indirect mechanisms linked to an increase in cAMP (discussed in Communi et al. [55] ), only the P2Y 11 receptor is directly coupled to activation of AC and PLC while P2Y 12 , P2Y 13 and P2Y 14 receptors negatively affect cAMP synthesis (Chambers et al. [13] ; Communi et al. [10] ; Hollopeter et al. [11] ; Zhang et al. [12] ). Adenylate cyclase-dependent signalling is often mediated by the cAMP-regulated kinase PKA. Stimulation of the P2Y 11 receptor with ATP is shown to activate human monocyte-derived dendritic cells by increased cAMP/PKA signalling (Wilkin et al. [74] ). In bovine adrenocortical fasciculate cells, ADP and ATP increase cortisol production through PKA activation by an as yet unidentified G s protein-coupled P2Y receptor (Nishi et al. [75] ). Although in unstimulated cells the cytosolic cAMP concentration is already low, its further decrease by G i protein-coupled receptors is sometimes sufficient to exert a significant inhibitory action towards PKA. Such a response is reported in microglial cells where ATP and ADP binding to P2Y 12/13 receptors mediate chemotaxis by PKA-dependent translocation of "1 integrins to ruffling regions of the cell (Nasu-Tada et al. [76] ).
Despite the fact that cells express a myriad of different GPCRs and downstream acting regulators, receptor stimulation promotes rapid and specific responses. In addition, multiple GPCRs, sharing the same second messenger cascade, can induce different cellular events in one cell type indicating that GPCR signal propagation requires physical interactions in a defined cellular compartment. An example of spatial organised signalling is the "-arrestin-dependent targeting of an activated receptor into clathrin-coated vesicles or enrichment in membrane microdomains (lipid rafts) formed by cholesterol and sphingolipids (Anderson [77] ; DeFea et al. [78] ). Modulation of receptor function by rafts is confirmed for an increasing number of GPCRs including P2Y receptors (Anderson [77] ; Ostrom and Insel [79] ). In endothelial cells, it is reported that P2Y receptor-induced vasodilatation is abolished by disruption of caveolae with methyl-"-cyclodextrin (Kaiser et al. [80] ). In C6 glioma cells, signalling by P2Y 2 and 5-hydroxytryptamine (HT) 2A receptors is attenuated after knock-down of caveolin-1 by si-RNA. Moreover, interaction between the 5-HT 2A receptor and caveolin-1 facilitates its interaction with G! q . Since P2Y 2 receptor mRNA is downregulated by caveolin-1 knock-down, further studies are required to demonstrate localisation of P2Y 2 receptors in caveolae of C6 cells (Bhatnagar et al. [81] ).
Small GTPases as molecular switches
The processing of extracellular stimuli by GPCRs often involves signalling by second messengers (cAMP, DAG, Ca 2+ ) towards small GTPases and/or cross-talk with tyrosine kinases. G q protein-coupled receptor signalling via PLC" induces formation of DAG and IP 3 , Ca 2+ mobilisation and activation of PKC ultimately leading to activation of proline-rich tyrosine kinase 2 (Pyk2). Pyk2 cooperates with Src to recruite Grb2 and SOS, a guanine nucleotide exchange factor (GEF) that activates Ras (Lev et al. [82] ). Such a mechanism is reported for Ras-dependent ERK activation induced by the protease-activated receptor-1 in astrocytes (Wang and Reiser [83] ). In PC12 cells, stimulation of the P2Y 2 receptor also triggers tyrosine phosphorylation of Pyk2, but further signalling to Ras involves EGFR transactivation by Src (Soltoff et al. [84] ). Tyrosine kinase-dependent Ras signalling is also reported for G i protein-coupled receptors, but this proceeds through G"+ subunit-mediated activation of PI 3-K+ and Shc (Ellis et al. [85] ; Lopez-Ilasaca et al. [86] ).
GEFs can also be regulated in a tyrosine kinaseindependent manner that proceeds through direct activation by cAMP, DAG and Ca 2+ or by interaction with G! subunits as observed for the G q/11 proteinmediated activation of RhoA (Bhattacharya et al. [87] ; Bos [88] ; Lutz et al. [89] ; Walker et al. [90] ).
P2Y receptor signalling towards GTPases is involved in short term responses, such as stress fibre formation or modulation of cell adhesion, but also in long term responses like cell proliferation. Mitogenic Ras-dependent P2Y responses are reported for C6 and HEK293 cells where Ras is implicated in P2Y 2 receptor-dependent signalling to the ERK pathway (Gao et al. [91] ; Tu et al. [44] ). On the other hand, increased proliferation of C6 cells by the P2Y 12 receptor proceeds independently of Ras, but requires RhoA-dependent activation of ERK and Rho-associated coiled-coilcontaining protein kinase (ROCK) (Grobben et al.
[40]; Van Kolen and Slegers, unpublished data). Interestingly, when the P2Y 12 receptor is expressed in CHO cells it activates ERK and RhoA/ROCK by independent mechanisms (Soulet et al. [92] ).
Another example of cross-talk between P2Y receptors and GTPases is observed in blood platelets. As mentioned above, release of ADP and subsequent P2Y 1 and P2Y 12 receptor binding is essential for collageninduced platelet aggregation. A crucial step for immediate and sustained aggregation of platelets is the activation of Rap1 that increases the affinity between integrin ! IIb " 3 and fibrinogen. Knock-out studies revealed that ADP-induced GTP loading of Rap1 proceeds through both G i and G q signalling by P2Y 12 and P2Y 1 receptors, respectively. The mechanism initiated by the P2Y 12 receptor is shown to be PI 3-K-dependent while P2Y 1 -mediated activation of Rap1 requires Ca 2+ mobilisation (Woulfe et al. [93] ; Greco et al. [94] ; Larson et al. [95] ; Lova et al. [96, 97] ). Stimulation of the P2Y 1 receptor also contributes to platelet shape changes by a Ca 2+ -independent pathway. RhoA and its effector ROCK are activated by ADP through G 12/13 protein-dependent signalling of the P2Y 1 receptor and contribute to rapid actin polymerization and shape changes (Paul et al. [98] [99] ). In the latter study, information concerning the signalling towards RhoA is lacking. In a more recent study on endothelial cells, transactivation of VEGFR upon P2Y 2 receptor stimulation and recruitment of the RhoGEF Vav is shown to be a possible mechanism to initiate RhoA-mediated cell adhesion (Seye et al. [100] ).
Although several P2Y receptors activate RhoA, downstream signalling and physiological consequences are determined by celltype specific mechanisms leading to diverse responses.
ERK signalling
Several GPCRs are coupled to enhanced proliferation by multiple signal transduction pathways that phosphorylate ERK. Activation of this kinase requires Ras or GTPases of the RhoA family and is often modulated by second messenger-activated pathways, although cross-talk with growth factor receptors also triggers ERK signalling.
In neurons G s protein-mediated activation of AC increases ERK phosphorylation by a PKA/Rap1/BRaf cascade. In contrast, induction of cAMP synthesis decreases ERK phosphorylation in C6 cells and astrocytes by a negative action of PKA on the Ras/cRaf1 interaction, or by Rap1-mediated inhibition of cRaf1. These observations led to the hypothesis that an increase in cAMP stimulates MEK/ERK signalling in B-Raf expressing cells but inhibits this cascade in BRaf negative cells (Dugan et al. [101] ). In both cases, PKA activation has a central role and mediates its effects through Src and Rap1 activation (Stork and Schmitt [102] ). Although the majority of cAMPdependent effects can be explained by this hypothesis, a few exceptions are reported. In some B-Raf positive cells, an increase in cAMP is shown to inhibit B-Raf, suggesting that regulation of this kinase by cAMP also depends on other cell type specific factors. One model suggests the involvement of 14-3-3 proteins acting as scaffolding proteins to shield B-Raf and Raf1 from PKA phosphorylation (Qiu et al. [103] ). Other studies indicated that regulation of ERK by cAMP involves multiple cell type specific mechanisms. In COS cells overexpressing "-AR1 or "-AR2, stimulation of these receptors activate AC through a G s protein-dependent mechanism as expected. However, PKA also phosphorylates these receptors and induces a switch from G s to G i/o protein binding to "-AR resulting in activation of ERK upon receptor stimulation (Martin et al. [104] ). Modulation of the ERK cascade by cAMP can also occur independently of PKA. In this context, cAMP binds Epac1 or Epac2, Bexchange protein directly activated by cAMP,'' GEFs that activate Rap1 and Rap2 (de Rooij et al. [105, 106] ; Kawasaki et al. [107] ). Several examples of G s protein-mediated activation of ERK through Epac are reported (Laroche-Joubert et al. [108] ; Lin et al. [109] ). Another PKA-independent mechanism of ERK phosphorylation is the G s "+/Src-mediated activation of Ras (Schmitt and Stork [110] [113] ). However, mutation of this serine residue into alanine does not affect Raf activity in response to phorbol esters (Yip-Schneider et al. [114] ). More convincing data were obtained when constitutively active PKC was expressed in rat 6 fibroblasts. These cells display Ras-independent signalling towards ERK by direct phosphorylation of Raf by PKC(. Since activation of Ras is required in several systems this interaction is cell type-dependent (Cacace et al. [115] ; Ueffing et al. [116] ). Direct phosphorylation of Raf by PKC is also involved in ERK activation by the G i protein-coupled leukotriene (LT)D 4 receptor in intestinal epithelial cells. Although stimulation of this receptor also triggers a parallel PKC-independent activation of Ras, transfection experiments confirmed that Ras is dispensable for LTD 4 receptor-mediated ERK activation (Paruchuri et al. [117] ). When constitutive active point mutants of PKC!, PKC% and PKC( were introduced in COS cells, only PKC% activated the ERK cascade (Ueda et al. [118] ), indicating that involvement of PKC isoforms in ERK signalling vary among different cell types. This is also confirmed by the observation that, in platelets, cPKCs are involved in thrombin-induced MEK and ERK activation independently of Ras or Raf (Nadal-Wollbold et al. [119] ).
G i/o protein-coupled receptors that are not linked to PLC activation can also modulate mitogenic signalling through G"+-dependent activation of PI 3-K+. Signalling from PI 3-K+ to ERK proceeds through Shc/Grb2/ SOS/Ras (Lopez-Ilasaca et al. [86] ). An increasing number of reports point to the involvement of PKCK in G i protein-dependent phosphorylation of ERK. The first observation was made in CHO cells where stimulation of the LPA receptor triggers MEK/ERK signalling via a PI 3-K+-dependent activation of PKCK not abrogated by transfection with dominant negative Ras (Takeda et al. [120] ). In addition, a recent report indicated that angiotensin II-induced ERK activation in rat vascular smooth muscle cells requires interaction between Ras and PKCK (Zhao et al. [121] ). PKCKdependent activation of ERK is mediated by interaction with MEK, a property shared by other PKC isoforms (Schö nwasser et al. [122] ), or by regulation of Raf1. Studies performed in rat embryonic hippocampal cells indicated that PKCK can phosphorylate the Raf kinase inhibitory protein (RKIP) resulting in dissociation of the Raf1/RKIP complex (Corbit et al. [123] ). In addition, co-immunoprecipitation experiments in COS cells showed that modulation of c-Raf1 by PKCK is also regulated by 14-3-3 scaffolding proteins (Van Der Hoeven et al. [124] ).
Initial studies concerning P2Y receptor-mediated activation of ERK were made in astrocytes where this cascade was shown to be involved in cell proliferation and process elongation (Neary and Zhu [125] ; King et al. [126] ).
Although ATP triggers pertussis toxin insensitive IP 3 and Ca 2+ responses in astrocytes, these are not required for the signalling towards ERK which depends on rapid membrane translocation of PKC% upon phosphatidylcholine hydrolysis by PLD (Neary et al. [73] ). In PC12 cells, stimulation of the P2Y 2 receptor also induces PKC%-dependent ERK phosphorylation, although this mechanism requires Ca 2+ and Pyk2 for the association of Shc and Grb2 to the receptor and for subsequent activation of SOS/Ras/ Raf/MEK/ERK (Soltoff et al. [84] ). Many reports showed that P2Y receptor-mediated ERK signalling requires PKC activation (Graham et al. [127] ; Huwiler and Pfeilschifter [128] ; Erlinge [129] ), but a PKCindependent mechanism is reported in thyroid FRTL-5 cells (Tornquist et al. [130] ). In 1321N1 astrocytoma cells, stimulation of the P2Y 6 receptor with UDP activates PKC!, ( and K which are correlated with ERK phosphorylation (Kim et al. [131] ). Although the use of general PKC inhibitors 3-[1-(dimethylaminopropyl) indol-3-yl]-4-(indol-3-yl)maleimide hydrochloride (GF109203X) and 12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole (Gö 6976) diminished ERK signalling, the lack of specificity of these compounds makes it difficult to determine the contribution of each of these PKC isoforms in the mechanism of ERK activation (Way et al. [132] In addition to mitogenesis, P2Y receptor signalling towards ERK elicits other physiological processes including cell survival, inflammation and reactive gliosis. In human lung microvascular endothelial cells, hyperoxia-induced release of ATP results in cell survival through ERK and PI 3-K signalling cascades activated by P2Y 2 and/or P2Y 6 receptors, while stimulation of the ERK cascade by the P2Y 6 receptor protects 1321N1 astrocytoma cells from TNF!-induced apoptosis (Ahmad et al. [134] ; Kim et al. [131] ). Rapid ERK1/2 and p38 MAPK activation plays an important role in P2Y 2 receptor-dependent primary granule release from human neutrophils (Meshki et al. [135] ). A similar phenomenon is observed in articular chondrocytes where ATP acts as a pro-inflammatory mediator by increasing arachidonic acid production and release of prostaglandin E 2 through a P2Y 2 receptordependent activation of p38 and ERK1/2 (Berenbaum et al. [136] ). In primary astrocytes, P2Y receptormediated ERK activation by ATP is shown to induce reactive astrogliosis, a phenomenon that occurs upon brain injury and is characterised by astroglial proliferation, cellular hypertrophy and up regulation of GFAP. This effect is mediated by an ERK-dependent increase in the expression of COX-2 (Brambilla et al. [53] ). In C6 cells, P2Y 12 and P2Y 2 receptor-induced activation of ERK is coupled to an enhanced cell proliferation, while a negative modulation of GFAP synthesis by the P2Y 12 ). These differences are probably due to the fact that in C6 cells induction of GFAP expression is not correlated with an enhanced proliferation but requires growth arrest.
In summary, most P2Y receptors are coupled to ERK phosphorylation, but the signalling mechanism and the physiological effect of this pathway are cell type specific and are determined by the cellular context. PI 3-K/PKB signalling PKB/Akt is involved in a large variety of cellular processes including glucose metabolism, mitogenesis, differentiation, survival and motility (Brazil et al. [137] ). This member of the AGC protein kinase superfamily is recruited to the plasmamembrane upon PI 3-K-mediated PIP3 formation, but is also controlled in a PI 3-K-independent, but calmodulin-dependent, fashion upon intracellular Ca 2+ mobilisation by stimulation of neuronal NMDA receptors (Cantley [138] ; Leevers et al. [139] ; Woodgett [140] ; Yano et al. [141] ).
Modulation of PKB activity is reported for a variety of GPCR ligands including adrenergics, cannabinoids, [146] ). Due to the existence of multiple phosphoinositide-dependent cascades, regulation of PKB signalling by GPCRs varies among the studied systems. In HEK293 cells, stimulation of "-AR with (-)-isoproterenol activates PKB via G s "+, Src, Ras and PI 3-K (Schmitt and Stork [110] ; Bommakanti et al. [147] ) while activation of AC by G! s exerts differential effects on PKB activity. In cells expressing Epac, cAMP activates PI 3-K/PKB via Rap1 while, in other cells, cAMP activates PKA that exerts a negative action on PI 3-K and PKB (Mei et al. [148] ; Wang et al. [149] ).
G i protein-mediated activation of PKB can occur through the coupling of the G"+ subunit to the catalytic subunit of PI 3-K or via growth factor receptor transactivation. Although only p110+ was initially reported to be activated by G"+ subunits, this feature is also observed for the p110" isoform (Kurosu et al. [150] ; Stoyanov et al. [151] ). This mechanism is reported in Vero cells where stimulation with LPA activates Ras upon increase in p110" lipid kinase activity (Yart et al. [152] ). G i protein-mediated transactivation of growth factor receptors is reported in HaCaT, A-431, and HEK293 cells where stimulation of the angiotensin type I receptor by mechanical stress induces transactivation of EGFR leading to activation of the PI 3-K/PKB cascade and protection of these cells from apoptosis (Kippenberger et al. [153] ).
In 1321N1 astrocytoma cells, PLC" activation by the G q protein-coupled muscarinic M 3 receptor also triggers PI 3-K activation through ErbB3 transactivation, but this mechanism requires Ca 2+ mobilisation (Tang et al. [154] ). In contrast, some reports showed an inhibitory pathway from G q protein-coupled receptors towards PI 3-K by direct interaction between G!-subunits released from heterotrimeric G proteins and p110!, as reported for the ! 1A -AR in rat-1 fibroblasts (Ballou et al. [155, 156] ), or by inhibition of insulin receptor substrate-1-associated PI 3-K activity in 1321N1 astrocytoma cells by carbachol, histamine or thrombin. These observations reveal opposing effects of muscarinic receptor stimulation on PI 3-K activity mediated by insulin and ErbB3 receptors in these cells (Batty et al. [157] ).
Modulation of PI 3-K/PKB signalling is also reported for a few P2Y receptors. In bovine adventitial fibroblasts, ATP is shown to induce proliferation through parallel but independent ERK and PI 3-K signalling cascades that contribute to mTOR and p70S6K phosphorylation (Gerasimovskaya et al. [158] ). In rat mesangial cells, stimulation of the P2Y 2 receptor with ATP or UTP activates PKB by a PDK-1-dependent mechanism while, in C6 cells, ADP activates PI 3-K/ PKB by the G i protein-coupled P2Y 12 receptor but inhibits PI 3-K by stimulation of the G q /G 11/12 proteincoupled P2Y 1 receptor ( [162] ). In human platelets, it was reported that P2Y 12 receptor activation potentiates P2Y 1 receptor-mediated Ca 2+ signalling, while the P2Y 1 receptor negatively regulates this action (Hardy et al. [163] ). In renal mesangial cells, P2Y receptors activated by ATP and UTP induce a rapid desensitisation of the sphingosine-1-phosphate (S1P) receptor by PKC-dependent phosphorylation (Xin et al. [164] ). A more complex interplay is observed between P2Y receptors and 5-HT receptor subtypes. Studies performed in CHO cells stably expressing 5-HT 1A receptors revealed that the responsiveness of this receptor is reduced by a PLD/PKC-dependent phosphorylation upon short (<5 min) pre-treatment with ATP, while the agonist efficacy of the overexpressed 5-HT 1B receptor is not altered. Alternatively, longer treatment with ATP alone attenuates 5-HT 1B signalling by a mechanism that requires activation of phospholipase A 2 (PLA 2 ) (Berg et al. [165] ). Furthermore, stimulation of P2Y receptors can also modulate the release of transmitter molecules, including dopamine, glutamate and serotonin (Bezzi and Voltera [52]; Krugel et al. [166] ; Nedergaard et al. [167] ). A recently discovered mechanism of GPCR cross-talk is the assembly of a heteromeric receptor complex displaying the pharmacological profile of one receptor and the signalling properties of the other. Such an interaction is reported in HEK293 cells overexpressing A 1 and P2Y 1 receptors. The heteromeric A 1 -P2Y 1 receptor complex inhibits AC through G i/o protein, but displays P2Y 1 receptorlike pharmacological properties (Yoshioka et al. [168] ).
P2Y receptor-mediated transactivation
Many studies reveal that GPCRs and growth factor receptors share a number of signalling modules (e.g., Raf/MEK/ERK, PI 3-K/PDK/PKB) to transduce their effects. In the past decade, it has become clear that the signalling pathways of both receptor systems are interconnected. Stimulation of a GPCR can induce a rapid tyrosine phosphorylation of RTKs. This transactivation mechanism is reported for many GPCRs and proceeds through the G"+ subunit-dependent activation of Src. Src in turn activates RTKs by phosphorylation of specific tyrosines located in their intracellular domains or induction of matrix metalloproteases-dependent release of growth factor receptor ligands, e.g., release of heparin-bound EGF (Luttrell and Luttrell [169] ).
Another target for signal integration of GPCRs and RTKs are docking proteins. Although these proteins contain phospho-tyrosine binding domains that interact with phosphorylated tyrosine residues of RTKs, stimulation of GPCRs can induce growth factor receptor-independent phosphorylation of docking proteins by Src (Bisotto and Fixman [170] ).
In addition to GPCR-dependent phosphorylation of RTKs, the opposite activation mechanism is also reported. Binding of PDGF to its cognate receptor induces association of PDGFR with the G i proteincoupled S1P receptor. Subsequently, Src is recruited to this complex by G"+ subunits and phosphorylates Grb-2 associated binder-1 resulting in dynamin II-induced Bpinching off'' of vesicles involved in endocytosis of PDGF-S1P signalling complexes and subsequent activation of ERK1/2 (Waters et al. [171] ).
Cross-talk between RTKs and P2Y receptors is reported in Mü ller glial cells where ATP exerts its mitogenic effect through transactivation of EGF and PDGF receptors resulting in ERK-dependent enhanced proliferation. In these cells, ATP-induced activation of ERK was abolished by treatment with the RTK autophosphorylation inhibitor tyrphostin (AG1478) (Milenkovic et al. [172] ). In rat striatal astrocytes, ATP and bFGF activate ERK and induce astrogliosis by a mechanism that is insensitive to RTK inhibition (Abbracchio et al. [173] ; Bolego et al. [174] ; Neary et al. [175] ). More recently, mechanistic studies performed in 1321N1 astrocytoma cells reveal that the human P2Y 2 receptor interacts with Src and Pyk2, probably by its proline-rich putative SH3 binding sites (PXXP). This interaction is implicated in P2Y 2 receptor-induced transactivation of EGF, PDGF and VEGF receptors (Liu et al. [176] ; Seye et al. [100] ). Src inhibition abolishes growth factor receptor transactivation and ERK phosphorylation. Although the rat P2Y 2 receptor lacks PXXP motives, tyrosine kinase-dependent activation of ERK upon P2Y 2 receptor stimulation is reported in a few rat cell lines, including C6 and PC12 cells (Soltoff et al. [84] ; Tu et al. [44] ). In the latter cases, P2Y 2 receptordependent activation of Pyk2 is mediated by PKC and Ca 2+ suggesting that the PXXP sequence is dispensable for P2Y 2 receptor-induced tyrosine phosphorylation of Pyk2 and downstream signalling towards ERK. Moreover, P2Y 2 mutants lacking PXXP-motives are still able to activate ERK demonstrating the existence of other pathways towards phosphorylation of ERK (Liu et al. [176] ). Observations made in human endothelial cells, where UTP-induced signalling to ERK was shown to depend on Ca 2+ , PKC and integrin-mediated cell anchorage, already pointed to a pathway distinct from the classical Ras/Raf/MEK/ ERK cascade (Short et al. [177] ). Human and mouse P2Y 2 receptors contain a RGD sequence which allows activation of ERK by interaction with ! V " 3 /" 5 integrins followed by G o protein coupling. Since these proteins also mediate cell adhesion and chemotaxis, the observed P2Y 2 /! V " 3 /" 5 -interaction also points to a possible function of P2Y 2 receptors in inflammatory responses (Erb et al. [178] ).
It is clear that, in analogy with other GPCRs, crosstalk between P2Y and growth factor receptors may occur at different levels of the signal transduction pathway depending on receptor subtypes and on the studied system. For the P2Y 2 receptor, additional transactivation mechanisms are facilitated by the presence of signalling motives (e.g., PXXP or RGD) that allow direct interaction with other signalling components (Src, integrins). The pathways involved in the P2Y receptor-dependent effects on growth and differentiation of these cells are presented in Figure 1 .
Nucleotides stimulate several purinergic receptors that activate the ERK cascade by at least two distinct mechanisms. The P2Y 2 receptor, stimulated by UTP and ATP, enhances ERK phosphorylation through a PLC"/PKC/Ras/Raf/MEK cascade that is attenuated by inhibition of tyrosine kinases and Ca 2+ chelation by BAPTA-AM (Tu et al. [44] ). The Ca 2+ -dependence of the P2Y 2 receptor-mediated activation of ERK suggests the involvement of a cPKC (!, "I, "II or +). It is also shown that ADP stimulates the P2Y 1 receptor and activates ERK through a Ca 2+ -dependent mechanism (Czajkowski et al. [46] ), likely by a similar mechanism as reported for the P2Y 2 receptor (Tu et al. [44] ). In addition, it has been shown that ADP can activate ERK by stimulation of the P2Y 12 receptor through a RhoA-and PKC-dependent pathway that does not require Ca 2+ , Ras or tyrosine kinase activation (Grobben et al. [40] ). The fact that Ca 2+ removal does not affect P2Y 12 receptor-mediated ERK activation excludes the involvement of cPKCs. Stimulation of the P2Y 12 receptor does not induce PI-turnover, but nPKCs might be involved since alternative activation mechanisms, based on Ser/Thr and Tyr phosphorylation, have been reported (Steinberg [180] ; Parekh et al. [181] ). Data from our laboratory suggest an important role for PKCK in P2Y 12 receptor-dependent activation of ERK. The fact that no cross-talk between ERK and PI 3-K is observed in C6 cells indicates that PKCK exerts its actions independently of PI 3-K via a RhoA- [185] ). Cyclic AMP-dependent inhibition of PKB and ERK is suggested to depend on inhibition of Rap1 (Wang et al. [149] ). The negative modulation of PI 3-K by the P2Y 1 [199] ). P2Y 12 receptor stimulation also inhibits cAMP-dependent induction of differentiation by reactivation of PKB which requires Src/Pyk2 complex formation and Rap1 activation. Formation of the Src/Pyk2 complex requires Ca 2+ and PLD2 which is constitutively active (Claes et al. [22] ; Van Kolen and Slegers [45]; Van Kolen et al. [185] ). Cyclic AMP-dependent inhibition of PKB and ERK is suggested to depend on inhibition of Rap1 (Wang et al. [149] ). The negative modulation of PI 3-K by the P2Y 1 receptor is only displayed in the presence of serum (Czajkowski et al.
[46]) dependent mechanism (Grobben et al. [40] ; Van Kolen and Slegers, [199] ). Although P2Y receptors use different mechanisms to activate ERK, they all converge to increased cell proliferation by enhanced synthesis of c-Myc, c-Jun and c-Fos (Zhang et al. [182] ). Progression through the G1/S phase of the cell cycle is due to a decreased expression of p27
Kip and increased expression of cyclinD.
While stimulation of ERK signalling by P2Y receptors has been known for several years, the coupling with PI 3-K activation was discovered more recently. When C6 cells are grown in the presence of serum, P2Y 1 receptor signalling predominates and is shown to inhibit PI 3-K (Czajkowski et al. [46] ). Upon serum deprivation, P2Y 1 receptor expression decreases while P2Y 12 becomes the main ADP-stimulated receptor that enhances the activity of PI 3-K by a G i proteindependent mechanism. These observations demonstrate that, in addition to autocrine growth factor receptor signalling, the constitutive PI 3-K activity in C6 cells is modulated by P2Y 1 [183] ). In addition to their opposing effects on PI 3-K/PKB signalling, unpublished data of our laboratory revealed similar modulation of ERK signalling by P2Y 12 and "-AR. Whether the P2Y 12 receptor-mediated reversal of ERK inhibition is involved in the inhibition of "-AR-induced GFAP synthesis remains to be determined. The observation that stimulation of the cells with UTP activates ERK, but fails to inhibit the "-AR-induced growth arrest and GFAP synthesis, suggests that ERK activation alone is not sufficient to counteract differentiation (Claes et al.
[39]; Tu et al. [44] ). Conversely, transfection of C6 cells with constutively active PKB prevented (-)-isoproterenol-induced differentiation indicating that inhibition of PKB signalling is required for cAMP-dependent induction of differentiation. Apparently this observation is in contrast with data showing that cAMPdependent induction of differentiation requires PI 3-K activity which is not inhibited upon a 48-h treatment with dbcAMP (Roymans et al. [34] ). This might be explained by the fact that induction of differentiation by stimulation of "-AR proceeds through transient inhibition of PKB while recovery of this activity is required to prohibit cell death. This hypothesis is confirmed by a recent study where sustained inhibition of PI 3-K/PKB by cannabinoids is shown to induce apoptosis in C6 cells (Table 2 ) (Ellert-Miklaszewska et al. [184] ). Taken together, P2Y 12 receptor stimulation inhibits cAMP-dependent induction of differentiation by a transient increase in PI 3-K/PKB activity. Ca 2+ chelation inhibits the basal PKB activity and P2Y 12 receptor-mediated increase in PKB phosphorylation. Although C6 cells also express the P2Y 2 receptor, stimulation with UTP does not enhance the activity of PI 3-K/PKB, which may be explained by a differential coupling to G protein subtypes. P2Y 2 receptor-mediated signalling proceeds through G q proteins while the activation of PDK is G i protein-dependent ( [159] ). The lack of G i protein coupling of the P2Y 2 receptor in C6 cells might be a consequence of compartimentalisation into caveolae as reported for some G q protein-coupled receptors (Bhatnagar et al. [81] ).
Although experiments in CHO cells reveal that P2Y 12 receptor-induced ERK activation requires PI 3-K+ (Soulet et al. [92] ), experiments performed with LY294002 or Wortmannin excluded cross-talk between both cascades in C6 cells (Grobben et al. [40] ). These differences in signalling mechanisms can be explained by the fact that the latter PI 3-K-isoform is only moderately expressed in C6 cells (Van Kolen and Slegers [45] ). The exact mechanism of P2Y 12 receptorinduced PI 3-K/PKB activation is not fully understood, but recent data revealed that Src and Pyk2 are involved in P2Y 12 receptor signalling to PI 3-K (Van Kolen et al., [185] ). A similar pathway is observed in PC12 cells where Src, in complex with Pyk2 and PLD2, activates PI 3-K in response to H 2 O 2 (Banno et al., [186] ). Since PLD2 is constitutively active in C6 cells (Bobeszko et al. [187] ), a significant role for this enzyme in PI 3-K/ Akt signalling is suggested. Although Soulet et al. [92] reported that transactivation of PDGFR is involved in PI 3-K activation by the P2Y 12 receptor in CHO cells, the use of receptor kinase inhibitors indicated that PDGFR and EGFR are not transactivated by the P2Y 12 receptor in C6 cells. Alternatively, a Rap1-mediated activation of PI 3-K by the P2Y 12 receptor cannot be excluded. Indeed, PI 3-K is postulated as a downstream effector of Rap1 that is inhibited by an increase in cAMP concentration (Wang et al. [149] ). Data from our laboratory indicated a rapid P2Y 12 receptor-induced activation of Rap1 that was abolished by Ca 2+ chelation and inhibition of Src/Pyk2 complex formation but not by PI 3-K inhibition (Van Kolen et al. [185] ). These results positioned Rap1 downstream of Src/Pyk2 but upstream of PI 3-K. In addition, this mechanism involves G"+ protein subunits and Ca 2+ -dependent activation of Pyk2 that requires association to IGF-IR and PLD2 to interact with Src. Although Src and Pyk2 are shown to activate Ras/Raf/MEK/ERK in primary astrocytes (Wang and Reiser [83] ), this mechanism did not contribute to P2Y 12 receptor-mediated ERK activation in C6 cells pointing to a physical separation of both cascades (Grobben et al. [40] ; Van Kolen and Slegers, [199] ). Indeed, the formation of a Pyk2/Src/ PLD2/IGFI-R complex may contribute to compartmentalisation of this signalling pathway that requires intact lipid rafts to be active (Van Kolen et al. [185] ). In contrast, in blood platelets Rap1, but also Pyk2 activation by the P2Y 12 receptor, depends on PI 3-K activity but is insensitive to Ca 2+ chelation (Lova et al. [96, 97] ; Koziak et al. [188] ). These findings indicate that different cell specific pathways are involved in P2Y 12 receptor-mediated activation of PI 3-K/PKB and additional research is required to allow full characterisation of these signalling cascades.
Conclusions
At present, nucleotides are known to regulate a variety of biological processes related to vascular-, immunological-and intestinal functioning. In vitro studies on glial and neuronal cells implicated the P2Y receptoractivated signalling pathways in regulation of cell motility, proliferation, chemotaxis and protection against oxidative stress. Furthermore, investigations on tumoral cells demonstrated that stimulation of P2Y receptors contribute to tumorigenesis by increasing cell proliferation through ERK and PKB signalling pathways activated by independent mechanisms. From these observations, a role of these receptors as potential targets in clinical applications emerges.
P2Y receptors modulate these physiological functions by activation of GTPases and direct or indirect activation of protein kinases. Characterisation of the involved receptor(s) and elucidation of P2Y receptorinduced activation of defined pathways needs to be improved by synthesis of specific P2Y agonists and antagonists.
Studies on P2Y receptor-mediated signalling, discussed in this review, demonstrate that besides vertical signal transduction, lateral cross-talk between growth factor receptors and GPCRs extends the signalling properties of a defined receptor subset. It also becomes clear that signal transduction pathways activated by P2Y receptors largely depend on the cell type and their environment. On the one hand, cellular specificity is determined by differential expression of signalling proteins, but on the other hand also depends on the assembly of signalling modules. Besides specific protein-protein interactions, intracellular compartmentalisation (e.g., lipid rafts, clathrin-coated vesicles) also contributes to the specificity of receptor signalling. Identification of the signalling modules and cellular compartmentalisation will provide more insight into the P2Y receptor-activated signalling cascades. 
